631 related articles for article (PubMed ID: 34143752)
1. SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
Kim JY; Kwon JS; Bae S; Cha HH; Lim JS; Kim MC; Chung JW; Park SY; Lee MJ; Kim BN; Jung J; Kim MJ; Shin EC; Kim SH
Am J Trop Med Hyg; 2021 Jun; 105(2):395-400. PubMed ID: 34143752
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
3. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
4. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.
Liu C; Yu X; Gao C; Zhang L; Zhai H; Hu Y; Liu E; Wang Q; Gao Y; Wei D; Zhang D; Han Y; Zhang X
J Med Virol; 2021 Apr; 93(4):2227-2233. PubMed ID: 33135795
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
6. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.
Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X
Front Immunol; 2021; 12():708523. PubMed ID: 34220870
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
8. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection.
Jiang XL; Wang GL; Zhao XN; Yan FH; Yao L; Kou ZQ; Ji SX; Zhang XL; Li CB; Duan LJ; Li Y; Zhang YW; Duan Q; Wang TC; Li ET; Wei X; Wang QY; Wang XF; Sun WY; Gao YW; Kang DM; Zhang JY; Ma MJ
Nat Commun; 2021 Feb; 12(1):897. PubMed ID: 33563974
[TBL] [Abstract][Full Text] [Related]
9. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
Front Immunol; 2021; 12():748291. PubMed ID: 34867975
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay.
Cassaniti I; Percivalle E; Bergami F; Piralla A; Comolli G; Bruno R; Vecchia M; Sambo M; Colaneri M; Zuccaro V; Benazzo M; Robotti C; Calastri A; Maiorano E; Ferrari A; Cambiè G; Baldanti F
Clin Microbiol Infect; 2021 Jul; 27(7):1029-1034. PubMed ID: 33813122
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Guo L; Wang Y; Kang L; Hu Y; Wang L; Zhong J; Chen H; Ren L; Gu X; Wang G; Wang C; Dong X; Wu C; Han L; Wang Y; Fan G; Zou X; Li H; Xu J; Jin Q; Cao B; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):664-676. PubMed ID: 33734013
[TBL] [Abstract][Full Text] [Related]
15. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
16. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
[TBL] [Abstract][Full Text] [Related]
17. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients.
Mohn KG; Bredholt G; Zhou F; Madsen A; Onyango TB; Fjelltveit EB; Jalloh SL; Brokstad KA; Cantoni D; Mayora-Neto M; Temperton N; Langeland N; Cox RJ;
PLoS One; 2022; 17(2):e0261979. PubMed ID: 35192617
[TBL] [Abstract][Full Text] [Related]
18. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Winckelmann AA; Bollerup S; Mikkelsen LS; Sørensen AL; Feng S; Fahnøe U; Lassauniere R; Fomsgaard A; Ramirez S; Weis N; Bukh J
EBioMedicine; 2021 Sep; 71():103519. PubMed ID: 34419923
[TBL] [Abstract][Full Text] [Related]
19. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
[TBL] [Abstract][Full Text] [Related]
20. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals.
Zhang J; Wu Q; Liu Z; Wang Q; Wu J; Hu Y; Bai T; Xie T; Huang M; Wu T; Peng D; Huang W; Jin K; Niu L; Guo W; Luo D; Lei D; Wu Z; Li G; Huang R; Lin Y; Xie X; He S; Deng Y; Liu J; Li W; Lu Z; Chen H; Zeng T; Luo Q; Li YP; Wang Y; Liu W; Qu X
Nat Microbiol; 2021 Jan; 6(1):51-58. PubMed ID: 33199863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
